Cantor Fitzgerald Has Weak Estimate for HRMY FY2025 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities research analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Harmony Biosciences in a report released on Thursday, February 20th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will earn $3.27 per share for the year, down from their prior forecast of $3.49. Cantor Fitzgerald has a “Overweight” rating and a $58.00 price target on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share.

A number of other research analysts also recently commented on HRMY. Needham & Company LLC lowered their price objective on Harmony Biosciences from $52.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday. Mizuho lowered their price objective on Harmony Biosciences from $52.00 to $42.00 and set an “outperform” rating for the company in a research note on Thursday. Deutsche Bank Aktiengesellschaft began coverage on Harmony Biosciences in a research note on Tuesday, February 11th. They set a “buy” rating and a $55.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $75.00 price objective on shares of Harmony Biosciences in a research note on Wednesday. Finally, Oppenheimer reiterated an “outperform” rating and set a $59.00 price target (up previously from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Harmony Biosciences currently has a consensus rating of “Buy” and a consensus target price of $53.67.

Harmony Biosciences Price Performance

Shares of HRMY opened at $34.89 on Friday. The company has a market cap of $1.99 billion, a P/E ratio of 16.54, a PEG ratio of 0.47 and a beta of 0.80. The stock has a fifty day moving average price of $36.53 and a 200 day moving average price of $35.74. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. Harmony Biosciences has a 12 month low of $28.14 and a 12 month high of $41.61.

Insider Transactions at Harmony Biosciences

In related news, CFO Sandip Kapadia sold 25,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.18, for a total transaction of $1,004,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jeffrey Dierks sold 1,123 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $40.00, for a total value of $44,920.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 72,452 shares of company stock worth $2,831,679. 30.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Harmony Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of HRMY. Deep Track Capital LP bought a new position in shares of Harmony Biosciences during the 4th quarter worth approximately $49,894,000. Vanguard Group Inc. lifted its position in shares of Harmony Biosciences by 36.4% during the 4th quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company’s stock worth $162,883,000 after buying an additional 1,262,362 shares during the period. Marshall Wace LLP lifted its position in shares of Harmony Biosciences by 165.2% during the 4th quarter. Marshall Wace LLP now owns 929,744 shares of the company’s stock worth $31,992,000 after buying an additional 579,103 shares during the period. Norges Bank bought a new position in shares of Harmony Biosciences during the 4th quarter worth approximately $16,118,000. Finally, Pacer Advisors Inc. lifted its position in shares of Harmony Biosciences by 18.2% during the 4th quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company’s stock worth $78,452,000 after buying an additional 351,582 shares during the period. Institutional investors own 86.23% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.